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IL-37 is a newly defined member of the IL-1 cytokine family. IL-37 expressed only in certain types of human organs 
and cells such as; testis, thymus, uterus, kidney, heart, peripheral blood mononuclear cells (PBMCs) and dendritic 
cells. It has been reported that IL-37 inhibited innate immunity and inflammatory responses in autoimmune diseases 
and tumors. Osteoclast recruitment might be central to diseases involving bone erosion, such as rheumatoid arthritis. 
Osteoclasts derived from bone marrow cells regulate bone resorption and remodeling. Two factors are required for 
osteoclasts formation and activation: receptor activator of NF-kB ligand (RANKL) and macrophage colony stimulating 
factor (M-CSF). It has also been reported that tumor necrosis factor (TNF)-α induced osteoclast formation in vitro 
and in vivo. Lipopolysaccharide (LPS), which is a bacterial cell wall component, is known as a potent inducer of 
inflammation. LPS is able to induce osteoclast formation and pathological bone resorption. LPS is also recognized 
to induce the production of many local factors, including proinflammatory cytokine such as TNF-α and IL-1, from 
macrophages or other cells in inflammatory site. These cytokines have been reported to associate with LPS-induced 
osteoclast formation and bone destruction in vivo and in vitro studies. Moreover, it has been reported that LPS 
stimulates osteoblasts to produce or secrete RANKL. IL-37 also inhibited Lipopolysaccharide (LPS)-induced 
immunological reaction. However, there is no study to investigate the effect of IL-37 on LPS-induced osteoclast 
formation and bone resorption. The purpose of this study is to investigate the effect of IL-37 in LPS-induced osteoclast 
formation and bone resorption. 
  LPS was administrated with or without IL-37 by subcutaneous injection on supracalvariae of mice. The number of 
osteoclasts, the level of mRNA for cathepsin K and tartrate-resistant acid phosphatase (TRAP), and the level of 
C-Terminal Telopeptide Fragments of Type I Collagen Cross-Links as a marker of bone resorption in mice administrated 
both LPS and IL-37 were lower than that in mice administrated LPS alone. Mice calvariae were observed using microfocal 
computed tomography images, many bone destruction spots were seen in the group administered LPS. The ratio of the 
bone destruction area in the LPS administered group was significantly higher than that in the PBS group and IL-37 
alone administrated group. In addition, in the LPS and IL-37 administered groups, bone destruction was lower than 
that in the LPS alone administered group. 
  Real-time RT-PCR was performed to analyze osteoclast related cytokines RANKL, TNF-α and IL-1β mRNA levels in 
vivo. RANKL, TNF-α and IL-1β mRNA was increased in the LPS administrated mice as compared with PBS administrated 
groups. On the other hand, RANKL, TNF-α and IL-1β mRNA was inhibited in the IL-37 and LPS administrated mice as 
compared with LPS alone administrated group.  
In vitro analysis, there was no effect of IL-37 in RANKL-induced osteoclast formation, TNF-α-induced osteoclast 
formation and cell viability from bone marrow macrophages as osteoclast precursor and LPS-induced RANKL expression 
from stromal cells.  
These results indicated that IL-37 inhibited LPS-induced osteoclast formation and bone resorption via inhibition 
of LPS-induced osteoclast related cytokines, but might not directly inhibit osteoclast formation on osteoclast 
precursor and RANKL expression on stromal cells. 
 
 
